Sunshine Nuohe: Subsidiary collaborates with Xinli Tai on new drug development, with milestone payments potentially reaching up to 850 million yuan

LightningPacketLoss

2026-03-21 09:18:22

Abstract generation in progress

Recently, Sunshine Nuohe announced that its wholly-owned subsidiary, Nuoheshengtai, has signed a Technology Licensing and Cooperative Development Agreement with Xinyi Tai to jointly develop the STC007 injection project.

According to the agreement, Xinyi Tai will obtain exclusive licensing rights for all itch-related indications of STC007 in the Chinese market, covering research and development, registration, manufacturing, and commercialization. Nuoheshengtai will receive an upfront payment and milestone payments for R&D, totaling up to 125 million yuan. If the product is approved for market launch, sales milestone payments could reach a total of 725 million yuan.

This collaboration is expected to have a positive impact on the company’s future performance and enhance its profitability. The contract execution will not affect the company’s core business independence, but it should be noted that Xinyi Tai still needs to obtain relevant government filings or approvals. Additionally, STC007 is currently in Phase II clinical trials, which involves certain uncertainties and risks.

(Sunshine Nuohe Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes